ALLR — Allarity Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $17.93m
- -$0.33m
Annual income statement for Allarity Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 8.43 | 26.7 | 34.5 | 17.1 | 27.2 |
| Operating Profit | -8.43 | -26.7 | -34.5 | -17.1 | -27.2 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.42 | -26.5 | -17.6 | -11.8 | -24.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.62 | -26.6 | -16.1 | -11.9 | -24.5 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.6 | -26.6 | -16.1 | -11.9 | -24.5 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.6 | -26.6 | -21.1 | -20.4 | -25.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -679,502 | -3,594,831 | -951,213 | -6,154 | -11.7 |